NVCR · Novocure Ltd

-

Please sign in to comment on NVCR

1 Comment

Admin

4 years ago

NovoCure Limited is currently in a long term uptrend where the price is trading 16.8% above its 200 day moving average.

From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 29.4.

NovoCure Limited's total revenue rose by 45.1% to $144M since the same quarter in the previous year.

Its net income has increased by 15.4% to $5M since the same quarter in the previous year.

Finally, its free cash flow grew by 1121.4% to $48M since the same quarter in the previous year.

Based on the above factors, NovoCure Limited gets an overall score of 5/5.

CurrencyCode	USD
ISIN	JE00BYSS4X48
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

PE Ratio	None
Market Cap	2B
Target Price	34.2857
Beta	0.65
Dividend Yield	None

ABOUT

Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NVCR · Novocure Ltd

-

Novocure Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Novocure Ltd using a moving average strategy